Innovating Works

ULTRANERVE

Financiado
Feasibility assessment of an all in one nerve repair and regeneration product
Peripheral Nerve Injuries (PNIs) are lesions of the nerves of the head or the extremities. Grand View Research estimates over 2 million cases of PNIs per year in the EU and the USA. These injuries remain incurable, resulting in pe... Peripheral Nerve Injuries (PNIs) are lesions of the nerves of the head or the extremities. Grand View Research estimates over 2 million cases of PNIs per year in the EU and the USA. These injuries remain incurable, resulting in permanent loss of body function as in paraplegia, leading to disabilities and heavy social burden. The chance to cure PNIs based on smart nano-engineered biomaterials will have a major positive impact in heavy and long term burdens on patients and healthcare systems. In this context, Nerve Biomed’s team, a spin-off company of the Polytechnic University of Valencia (Spain) has been leading an R&D initiative in advanced PNI reparation over the past 11 years, in order to develop and further commercialise ULTRANERVE: an easy-to-use medical solution for PNI regeneration, which is going to simplify medical procedures and reduce the average full recovery time, while decreasing significantly the average cost of actual repair procedures. Within the roadmap established by the company to commercialize the product internationally by 2020, Nerve Biomed wants to perform a thorough feasibility study, through this SME Instrument Phase 1, which will assess in detail the practical and economic viability of introducing this solution in the PNI repair and regeneration market ih the EU and the USA. ver más
30/09/2017
71K€
Duración del proyecto: 4 meses Fecha Inicio: 2017-05-23
Fecha Fin: 2017-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2017-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
NERVE BIOMED SL C.n.a.e. 7211. la sociedad tendrá por objeto: la actividad principal de la empresa será la investigación, el desarrollo y la innovación, así...
Perfil tecnológico TRL 3-4 50K